Last reviewed · How we verify
Cord Blood Cell
Cord blood-derived cells promote neural regeneration and functional recovery in spinal cord injury through cell replacement, neuroprotection, and anti-inflammatory effects.
Cord blood-derived cells promote neural regeneration and functional recovery in spinal cord injury through cell replacement, neuroprotection, and anti-inflammatory effects. Used for Spinal cord injury.
At a glance
| Generic name | Cord Blood Cell |
|---|---|
| Sponsor | China Spinal Cord Injury Network |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Cord blood cells, typically hematopoietic stem cells or other progenitor cells, are transplanted into the injured spinal cord where they may differentiate into neural cells, secrete neurotrophic factors, and modulate the inflammatory microenvironment. This multi-modal approach aims to restore lost neural tissue, protect surviving neurons, and promote axonal regeneration and functional motor/sensory recovery.
Approved indications
- Spinal cord injury
Common side effects
- Infection at transplant site
- Immune rejection
- Pain at injection site
- Neurological complications
Key clinical trials
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 (PHASE3)
- Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (PHASE1)
- Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome (PHASE1, PHASE2)
- Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma (PHASE1)
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
- Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
- Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis (PHASE3)
- Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cord Blood Cell CI brief — competitive landscape report
- Cord Blood Cell updates RSS · CI watch RSS
- China Spinal Cord Injury Network portfolio CI